Intra-articular administration of hylan G-F 20 in patients with symptomatic hip osteoarthritis: tolerability and effectiveness in a large cohort study in clinical practice

Migliore, Alberto; Tormenta, Sandro; Massafra, Umberto; Bizzi, Emanuele; Iannessi, F.; Alimonti, Andrea; Granata, M.

doi:10.1185/030079908x291930

Cited by 35 publications

(25 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is good evidence that BMI does not predict response to COX-2 inhibitors for hip and knee OA management (20,21). The evidence is weak that BMI is not predictive of treatment response to either a multi-modal stepped-care pain management model (18,19), hip CSI (22) hip IA Hylan G-F20 (27), or glucosamine for chronic knee pain (28). The evidence for BMI as a predictor of response to knee IA Hylan G-F is weak and conflicting (23)(24)(25)(26).…”

Section: Body Mass Indexmentioning

confidence: 99%

“…Treatment response was defined as a ≥30% improvement in baseline Lequesne scores or NSAID usage at 6 months, the number of participants classified as responders was unclear. Ten possible predictors of treatment response were analysed, BMI was not a significant predictor of response to hip IA Hylan G-F 20 (27). The large number of drop-outs (42%) affected the validity of this study.…”

Section: Body Mass Indexmentioning

confidence: 99%

“…Three cohort studies attempted to identify radiographic characteristics of patients with hip and knee OA that were predictive of treatment response to IA Hylan G-F 20 (24,25,27). Migliore et al (2008) followed 250 patients who received US-guided IA hylan G-F 20 into OA hips (27).…”

Section: Radiographic and Mri Assessmentmentioning

confidence: 99%

“…Migliore et al (2008) followed 250 patients who received US-guided IA hylan G-F 20 into OA hips (27). Treatment response was defined as improvement of ≥30% Lequesne index or NSAID use.…”

Section: Radiographic and Mri Assessmentmentioning

confidence: 99%

“…Migliore et al (2008) evaluated 250 patients with hip OA who received intra articular Hylan G-F20 (27). Treatment response was defined as a ≥30% improvement in baseline Lequesne scores or NSAID usage at 6 months, the number of participants classified as responders was unclear.…”

Section: Body Mass Indexmentioning

confidence: 99%

See 4 more Smart Citations

Targeting Care

Eyles

Lucas

Hunter

2013

Rheumatic Disease Clinics of North America

View full text Add to dashboard Cite

Important points and objectives for recall:• Numerous studies have explored patient characteristics including: body mass index, psychological factors, muscle strength, tibiofemoral alignment, radiographic changes and signs of inflammation as potential predictors of response to non-surgical interventions for management of hip and knee OA.• Often the sample sizes utilized by these studies were inadequate to yield sufficient numbers of responders to the interventions to allow for analysis of the potential predictors identified.• A number of well-designed studies were adequately powered to provide some evidence for clinical characteristics that did or did not predict response to non-surgical interventions for participants with hip and knee OA. SynopsisInternational evidence-based guidelines recommend a multitude of non-surgical treatment options for the management of OA. In the face of so many choices, it would be helpful for clinicians to be able to base treatment decisions on the identification of specific clinical presentations that foretell greater likelihood of success following a given treatment. This review summarizes the evidence available for patient characteristics that have been analysed as potential predictors of response to non-surgical interventions for patients with hip and knee OA. The specific variables targeted for this review include: body mass index, psychological factors, muscle strength, tibiofemoral alignment, radiographic changes and signs of inflammation. Several studies provide moderate to good evidence of potential predictors of response to non-surgical treatments, while areas for future research are illuminated.

show abstract

Section: Body Mass Indexmentioning

confidence: 99%

Section: Body Mass Indexmentioning

confidence: 99%

Section: Radiographic and Mri Assessmentmentioning

confidence: 99%

“…Migliore et al (2008) followed 250 patients who received US-guided IA hylan G-F 20 into OA hips (27). Treatment response was defined as improvement of ≥30% Lequesne index or NSAID use.…”

Section: Radiographic and Mri Assessmentmentioning

confidence: 99%

Section: Body Mass Indexmentioning

confidence: 99%

See 3 more Smart Citations

Targeting Care

Eyles

Lucas

Hunter

2013

Rheumatic Disease Clinics of North America

View full text Add to dashboard Cite

show abstract

Sorbitol-modified hyaluronic acid reduces oxidative stress, apoptosis and mediators of inflammation and catabolism in human osteoarthritic chondrocytes

et al. 2014

View full text Add to dashboard Cite

show abstract

Viscosupplementation in the management of ankle osteoarthritis: a review

Migliore

Giovannangeli

Bizzi

et al. 2010

Arch Orthop Trauma Surg

View full text Add to dashboard Cite

Viscosupplementation is used widely in knee OA and is included in the professional guidelines for treatment of the disease in this joint. The potential for treating osteoarthritis of the ankle joint by viscosupplementation has been suggested in the literature, however, no dosing studies have been published to date, and dosing in the ankle joint remains an area for discussion. Viscosupplementation could potentially provide an useful alternative in treating such patients with painful ankle OA.

show abstract

Intra-articular administration of hylan G-F 20 in patients with symptomatic hip osteoarthritis: tolerability and effectiveness in a large cohort study in clinical practice

Cited by 35 publications

References 32 publications

Targeting Care

Targeting Care

Sorbitol-modified hyaluronic acid reduces oxidative stress, apoptosis and mediators of inflammation and catabolism in human osteoarthritic chondrocytes

Viscosupplementation in the management of ankle osteoarthritis: a review

Contact Info

Product

Resources

About